AbbVie Details Senior Notes in Latest 8-K Filing

Ticker: ABBV · Form: 8-K · Filed: 2024-02-26T00:00:00.000Z

Sentiment: neutral

Topics: debt, corporate-finance, filing

TL;DR

**AbbVie just updated its debt structure, detailing various senior notes with different maturities and interest rates.**

AI Summary

AbbVie Inc. filed an 8-K on February 26, 2024, reporting on "Other Events" and "Financial Statements and Exhibits" as of February 22, 2024. The filing details various senior notes with different interest rates and maturity dates, including 1.375% due 2024, 1.250% due 2024, 0.750% due 2027, 2.125% due 2028, 2.625% due 2028, 2.125% due 2029, and 1.250% due 2031. This indicates ongoing financial activities related to its debt structure.

Why It Matters

This filing provides transparency into AbbVie's current debt obligations and financing activities, which can influence its financial health and future investment capacity.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of existing debt instruments and does not indicate new, significant risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of AbbVie Inc.'s 8-K filing dated February 26, 2024?

The 8-K filing by AbbVie Inc. on February 26, 2024, is for "Other Events" and "Financial Statements and Exhibits," specifically detailing various senior notes as of February 22, 2024.

What are the interest rates and maturity dates of the senior notes mentioned in the filing?

The filing mentions senior notes with interest rates of 1.375% due 2024, 1.250% due 2024, 0.750% due 2027, 2.125% due 2028, 2.625% due 2028, 2.125% due 2029, and 1.250% due 2031.

When was the conformed period of report for this 8-K filing?

The conformed period of report for this 8-K filing was February 22, 2024.

What is AbbVie Inc.'s ticker symbol and par value for common stock?

AbbVie Inc.'s ticker symbol is ABBV, and its common stock has a $0.01 par value.

Where is AbbVie Inc.'s business address?

AbbVie Inc.'s business address is 1 North Waukegan Road, North Chicago, IL 60064.

From the Filing

0001104659-24-027585.txt : 20240226 0001104659-24-027585.hdr.sgml : 20240226 20240226170837 ACCESSION NUMBER: 0001104659-24-027585 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 26 CONFORMED PERIOD OF REPORT: 20240222 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24680063 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm246405d5_8k.htm FORM 8-K false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2024-02-22 2024-02-22 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-02-22 2024-02-22 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2024-02-22 2024-02-22 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2024-02-22 2024-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024       ABBVIE INC. (Exact name of registrant as specified in its charter)       Delaware   001-35565   32-0375147 (State of Incorporation)   (Commission File Number)   (IRS Employer Identification Number)   1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices, including zip code)   ( 847 ) 932-7900 (Registrant’s telephone number, including area code)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on whic

View on Read The Filing